<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01027910</url>
  </required_header>
  <id_info>
    <org_study_id>09-352</org_study_id>
    <nct_id>NCT01027910</nct_id>
  </id_info>
  <brief_title>PCI-24781 in Combination With Doxorubicin to Treat Sarcoma</brief_title>
  <official_title>Phase I/II Study of PCI-24781 in Combination With Doxorubicin for Treatment of Advanced Sarcomas Following Failure or Prior Anthracycline Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pharmacyclics LLC.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine the safety and maximum tolerated dose of
      PCI-24781 that can be given safely with doxorubicin (phase I) and the safety and efficacy of
      PCI-24781 when used in combination with doxorubicin (phase II) in patients with advanced
      sarcomas. The study drug, PCI-24781, is believed to regulate genes involved in tumor cell
      growth. The other study drug, doxorubicin, is considered a standard chemotherapeutic
      treatment for advanced sarcoma patients. We hypothesize that combining PCI-24781 with
      doxorubicin can overcome chemoresistance to doxorubicin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  In the phase I portion of the study, since we are looking for the highest dose of
           PCI-24781 that can be administered safely without severe or unmanageable side effects in
           participants that have advanced sarcoma, not everyone who participates in this research
           study will receive the same dose of PCI-24871.

        -  Each treatment cycle is 3 weeks (21 days). Participants will take capsules of PCI-24871
           for five consecutive days starting on Day 1 of each 3 week cycle. On Day 4 of each
           cycle, participants will come to the clinic to receive doxorubicin intravenously.

        -  At specific time intervals, participants will return to the clinic for the following
           tests and procedures: physical examination, vital signs, blood tests, urine test, EKG,
           assessment of the tumor by CT scan, and an ECHO or MUGA.

        -  Participants may remain on the study for a maximum of 6 cycles (about 4-5 months). After
           the last cycle, as long as the participant is showing benefit, they may elect to
           continue taking PCI-24781 alone, in which case they will continue in this research study
           until there is evidence of their tumor growing.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>up to 30 days after starting study drugs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose Limiting Toxicities</measure>
    <time_frame>1 year</time_frame>
    <description>number of patients who experienced dose limiting toxicities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Partial Responses (PR)</measure>
    <time_frame>1 year</time_frame>
    <description>number of patients who demonstrated partial response to therapy as determined by RECIST v1.0 for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Progression-free Survival at 6 Months in Participants Who Received PCI-24781/Doxorubicin Combination Administration.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>PCI-24781 without mandated GCSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PCI-24781 in combination with doxorubicin without mandated GCSF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCI-24781 with mandated GCSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PCI-24781 in combination with doxorubicin with mandated GCSF</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PCI-24781</intervention_name>
    <description>Capsules taken orally for 5 consecutive days starting on Day 1 of each 3 week cycle</description>
    <arm_group_label>PCI-24781 without mandated GCSF</arm_group_label>
    <arm_group_label>PCI-24781 with mandated GCSF</arm_group_label>
    <other_name>PCI24781</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Administered intravenously on Day 4 of each 3 week cycle</description>
    <arm_group_label>PCI-24781 without mandated GCSF</arm_group_label>
    <arm_group_label>PCI-24781 with mandated GCSF</arm_group_label>
    <other_name>Adriamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GCSF</intervention_name>
    <description>Administered on Day 5 of each 3 weeks cycle in Arm 1 if determined to be clinically indicated, and in all patients enrolled into Arm 2</description>
    <arm_group_label>PCI-24781 without mandated GCSF</arm_group_label>
    <arm_group_label>PCI-24781 with mandated GCSF</arm_group_label>
    <other_name>Neupogen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must have histologically confirmed metastatic or unresectable sarcoma

          -  All participants must have received no more than a lifetime cumulative maximum dose of
             300 mg/m2 or less of prior doxorubicin and no other anthracycline therapy.

          -  Participants must have measurable disease, defined as at least one unirradiated lesion
             that can be accurately measured in at least one dimension as 20mm or greater with
             conventional techniques or as 10mm or greater with spiral CT scan.

          -  ECOG performance status of 2 or less

          -  Ability to swallow oral capsules without difficulty

          -  Participants must have normal organ and marrow function as outlined in the protocol.

          -  Women of childbearing potential must have a negative serum/urine pregnancy test within
             7 days prior to receiving the first dose of PCI-24781.

          -  An ECHO or MUGA demonstrating EF &gt; 50% is required within 4 weeks prior to study drug
             administration.

          -  18 years of age or older

        Exclusion Criteria:

          -  Participants who have had immunotherapy, chemotherapy, experimental therapy or
             radiotherapy within 4 weeks before first day of study drug dosing or those who have
             not recovered to grade 1 or baseline from adverse events due to agents administered
             more than 4 weeks earlier.

          -  Participants who have previously received &gt; 300 mg/m2 cumulative lifetime dose of
             doxorubicin, or who have received any other anthracycline chemotherapy.

          -  Major surgery within 4 weeks before first day of study drug dosing

          -  Participants with known central nervous system/brain metastases

          -  Participants receiving chronic corticosteroids &gt; 20 mg prednisone equivalent per day
             for &gt; 7 consecutive days (Topical, inhaled or nasal corticosteroids are permitted).

          -  Participants with any documented malabsorption syndromes or other conditions that may
             impair the absorption of PCI-24781 capsules.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Participants requiring concurrent therapeutic anticoagulation or have received
             therapeutic anticoagulation within 2 weeks of the first day of dosing.

          -  Risk factors for Torsades de Pointes, or use, within 4 weeks of starting study drug
             administration, of medications known to prolong QTc interval or that may be associated
             with Torsades de Pointes.

          -  QTc prolongation or other significant ECG abnormalities defined as 2nd degree AV block
             type II, 3rd degree AV block, or bradycardia.

          -  History of myocardial infarction, acute coronary syndromes, coronary angioplasty
             and/or coronary artery stenting within the past 6 months.

          -  For patients with history of major coronary artery disease in the judgement of the
             responsible physician, a cardiac stress test that demonstrates clinically significant
             abnormalities when performed within 28 days of first dose of study drug

          -  Pregnant or breastfeeding women

          -  Women of childbearing potential, or sexually active men unwilling to use adequate
             contraceptive protection during the course of the study

          -  HIV-positive individuals

          -  Other medical or psychiatric illness or organ dysfunction that, in the opinion of the
             investigator, would either compromise the patient's safety or interfere with the
             evaluation of the safety of PCI-24781
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edwin Choy, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lopez G, Liu J, Ren W, Wei W, Wang S, Lahat G, Zhu QS, Bornmann WG, McConkey DJ, Pollock RE, Lev DC. Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma. Clin Cancer Res. 2009 May 15;15(10):3472-83. doi: 10.1158/1078-0432.CCR-08-2714. Epub 2009 May 5. Erratum in: Clin Cancer Res. 2015 Apr 1;21(7):1774-5.</citation>
    <PMID>19417021</PMID>
  </reference>
  <reference>
    <citation>Buggy JJ, Cao ZA, Bass KE, Verner E, Balasubramanian S, Liu L, Schultz BE, Young PR, Dalrymple SA. CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. Mol Cancer Ther. 2006 May;5(5):1309-17.</citation>
    <PMID>16731764</PMID>
  </reference>
  <reference>
    <citation>Adimoolam S, Sirisawad M, Chen J, Thiemann P, Ford JM, Buggy JJ. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19482-7. Epub 2007 Nov 27.</citation>
    <PMID>18042714</PMID>
  </reference>
  <reference>
    <citation>Yang C, Choy E, Hornicek FJ, Wood KB, Schwab JH, Liu X, Mankin H, Duan Z. Histone deacetylase inhibitor PCI-24781 enhances chemotherapy-induced apoptosis in multidrug-resistant sarcoma cell lines. Anticancer Res. 2011 Apr;31(4):1115-23.</citation>
    <PMID>21508354</PMID>
  </reference>
  <reference>
    <citation>Yang C, Choy E, Hornicek FJ, Wood KB, Schwab JH, Liu X, Mankin H, Duan Z. Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells. Cancer Chemother Pharmacol. 2011 Feb;67(2):439-46. doi: 10.1007/s00280-010-1344-7. Epub 2010 May 12.</citation>
    <PMID>20461381</PMID>
  </reference>
  <reference>
    <citation>Lopez G, Torres K, Liu J, Hernandez B, Young E, Belousov R, Bolshakov S, Lazar AJ, Slopis JM, McCutcheon IE, McConkey D, Lev D. Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors. Cancer Res. 2011 Jan 1;71(1):185-96. doi: 10.1158/0008-5472.CAN-10-2799. Epub 2010 Nov 16. Erratum in: Cancer Res. 2015 Apr 15;75(8):1771-4.</citation>
    <PMID>21084276</PMID>
  </reference>
  <reference>
    <citation>Choy E, Flamand Y, Balasubramanian S, Butrynski JE, Harmon DC, George S, Cote GM, Wagner AJ, Morgan JA, Sirisawad M, Mani C, Hornicek FJ, Duan Z, Demetri GD. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma. Cancer. 2015 Apr 15;121(8):1223-30. doi: 10.1002/cncr.29175. Epub 2014 Dec 23.</citation>
    <PMID>25536954</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2009</study_first_submitted>
  <study_first_submitted_qc>December 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2009</study_first_posted>
  <results_first_submitted>March 9, 2016</results_first_submitted>
  <results_first_submitted_qc>December 21, 2016</results_first_submitted_qc>
  <results_first_posted type="Actual">February 14, 2017</results_first_posted>
  <last_update_submitted>December 21, 2016</last_update_submitted>
  <last_update_submitted_qc>December 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Edwin Choy, MD</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>PCI-24781</keyword>
  <keyword>doxorubicin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Abexinostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PCI-24781 + Doxorubicin Without Mandatory GCSF</title>
          <description>PCI-24781 + Doxorubicin without mandatory GCSF
PCI-24781: Capsules taken orally for 5 consecutive days starting on Day 1 of each 3 week cycle
Doxorubicin: Administered intravenously on Day 4 of each 3 week cycle</description>
        </group>
        <group group_id="P2">
          <title>PCI-24781 + Doxorubicin With Mandatory GCSF</title>
          <description>PCI-24781 + Doxorubicin with mandatory GCSF
PCI-24781: Capsules taken orally for 5 consecutive days starting on Day 1 of each 3 week cycle
Doxorubicin: Administered intravenously on Day 4 of each 3 week cycle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PCI-24781 + Doxorubicin Without Mandatory GCSF</title>
          <description>Study participants were enrolled into two arms. Arm A administered abexinostat and doxorubicin with optional GCSF support. Arm B administered abexinostat and doxorubicin with required GCSF support to all participants. The study uses the standard 3 + 3 phase I dose escalation design. Three cohorts of 3-6 participants were enrolled in each arm and separate inter-cohort dose escalations were performed in up to three cohorts of 3-6 participants enrolled sequentially until the maximum tolerated dose (MTD) of the combination abexinostat with doxorubicin, without (Arm A) mandatory G-CSF support was established.</description>
        </group>
        <group group_id="B2">
          <title>PCI-24781 + Doxorubicin With Mandatory GCSF</title>
          <description>Study participants were enrolled into two arms. Arm A administered abexinostat and doxorubicin with optional GCSF support. Arm B administered abexinostat and doxorubicin with required GCSF support to all participants. The study uses the standard 3 + 3 phase I dose escalation design. Three cohorts of 3-6 participants were enrolled in each arm and separate inter-cohort dose escalations were performed in up to three cohorts of 3-6 participants enrolled sequentially until the maximum tolerated dose (MTD) of the combination abexinostat with doxorubicin, with (Arm B) mandatory G-CSF support was established.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" spread="14"/>
                    <measurement group_id="B2" value="56" spread="14"/>
                    <measurement group_id="B3" value="54" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose</title>
        <time_frame>up to 30 days after starting study drugs</time_frame>
        <population>The two groups differ in that GCSF was offered if clinically indicated in arm 1 while it was administered to all participants in arm 2.</population>
        <group_list>
          <group group_id="O1">
            <title>PCI-24781 + Doxorubicin Without Mandatory GCSF</title>
          </group>
          <group group_id="O2">
            <title>PCI-24781 With Mandatory GCSF</title>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose</title>
          <population>The two groups differ in that GCSF was offered if clinically indicated in arm 1 while it was administered to all participants in arm 2.</population>
          <units>mg/m2</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose Limiting Toxicities</title>
        <description>number of patients who experienced dose limiting toxicities</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Optional GCSF</title>
          </group>
          <group group_id="O2">
            <title>Mandatory GCSF</title>
          </group>
        </group_list>
        <measure>
          <title>Dose Limiting Toxicities</title>
          <description>number of patients who experienced dose limiting toxicities</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Partial Responses (PR)</title>
        <description>number of patients who demonstrated partial response to therapy as determined by RECIST v1.0 for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Optional GCSF</title>
          </group>
          <group group_id="O2">
            <title>Mandatory GCSF</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Partial Responses (PR)</title>
          <description>number of patients who demonstrated partial response to therapy as determined by RECIST v1.0 for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Progression-free Survival at 6 Months in Participants Who Received PCI-24781/Doxorubicin Combination Administration.</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Optional GCSF</title>
          </group>
          <group group_id="O2">
            <title>Mandatory GCSF</title>
          </group>
        </group_list>
        <measure>
          <title>Rate of Progression-free Survival at 6 Months in Participants Who Received PCI-24781/Doxorubicin Combination Administration.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PCI-24781+Dox Without Mandated GCSF</title>
          <description>Patients in this arm were not mandated treatment with GCSF</description>
        </group>
        <group group_id="E2">
          <title>PCI-24781+Dox With Mandated GCSF</title>
          <description>Patients in this are were mandated treatment with GCSF</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>grade 3 or 4 neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Edwin Choy</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-724-4000</phone>
      <email>echoy@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

